These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18658150)

  • 1. SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.
    Agarwal R; Swaminathan S
    J Biol Chem; 2008 Sep; 283(38):25944-51. PubMed ID: 18658150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E.
    Chen S; Barbieri JT
    J Biol Chem; 2007 Aug; 282(35):25540-7. PubMed ID: 17609207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique substrate recognition by botulinum neurotoxins serotypes A and E.
    Chen S; Barbieri JT
    J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate binding mode and its implication on drug design for botulinum neurotoxin A.
    Kumaran D; Rawat R; Ahmed SA; Swaminathan S
    PLoS Pathog; 2008 Sep; 4(9):e1000165. PubMed ID: 18818739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.
    Zuniga JE; Schmidt JJ; Fenn T; Burnett JC; Araç D; Gussio R; Stafford RG; Badie SS; Bavari S; Brunger AT
    Structure; 2008 Oct; 16(10):1588-97. PubMed ID: 18940613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity.
    Jin R; Sikorra S; Stegmann CM; Pich A; Binz T; Brunger AT
    Biochemistry; 2007 Sep; 46(37):10685-93. PubMed ID: 17718519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of substrate recognition by botulinum neurotoxin serotype A.
    Chen S; Kim JP; Barbieri JT
    J Biol Chem; 2007 Mar; 282(13):9621-9627. PubMed ID: 17244603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.
    Ho M; Goh CH; Brothers MC; Wang S; Young RL; Ou Y; Lui JN; Kalafatis M; Lan X; Wolf AE; Rienstra CM; Wilson BA
    Protein Sci; 2012 Mar; 21(3):318-26. PubMed ID: 22170566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW; Chai Q; Christian T; Stevens RC
    Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL
    Cesar Ramos de Jesus H; Solis N; Machado Y; Pablos I; Bell PA; Kappelhoff R; Grin PM; Sorgi CA; Butler GS; Overall CM
    J Virol; 2024 Jun; 98(6):e0004924. PubMed ID: 38742901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
    Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
    Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
    Chen S; Hall C; Barbieri JT
    J Biol Chem; 2008 Jul; 283(30):21153-9. PubMed ID: 18511417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the different catalytic activities of Clostridium neurotoxins.
    Chen S; Karalewitz AP; Barbieri JT
    Biochemistry; 2012 May; 51(18):3941-7. PubMed ID: 22510015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A.
    Kumaran D; Rawat R; Ludivico ML; Ahmed SA; Swaminathan S
    J Biol Chem; 2008 Jul; 283(27):18883-91. PubMed ID: 18434312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
    Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
    Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
    Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
    Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
    Ahmed SA; Olson MA; Ludivico ML; Gilsdorf J; Smith LA
    Protein J; 2008 Apr; 27(3):151-62. PubMed ID: 18213512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage.
    Vaidyanathan VV; Yoshino K; Jahnz M; Dörries C; Bade S; Nauenburg S; Niemann H; Binz T
    J Neurochem; 1999 Jan; 72(1):327-37. PubMed ID: 9886085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
    Agarwal R; Binz T; Swaminathan S
    Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin.
    Schmidt JJ; Bostian KA
    J Protein Chem; 1997 Jan; 16(1):19-26. PubMed ID: 9055204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.